Page last updated: 2024-11-05

glycidol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glycidol is a three-membered cyclic ether and a chiral molecule that finds applications as a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and polymers. Its synthesis is typically achieved through the epoxidation of allyl alcohol using hydrogen peroxide in the presence of a catalyst, such as a tungsten-based catalyst. Glycidol exhibits several biological effects, including its ability to inhibit cell growth and induce apoptosis. It also possesses antimicrobial activity against various bacterial and fungal strains. Glycidol is studied extensively due to its potential applications in various fields. Its reactivity as a chiral epoxide makes it a valuable intermediate in organic synthesis, enabling the production of diverse chiral compounds. Glycidol's cytotoxic and antimicrobial properties make it a subject of interest in the development of novel therapeutic agents. Further research focuses on understanding its impact on human health and the environment, as it is considered a potential health hazard due to its carcinogenic properties.'

glycidol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11164
CHEMBL ID1530150
CHEBI ID30966
MeSH IDM0045323

Synonyms (112)

Synonym
AKOS009031473
MLS002174255
smr001261426
EN300-19950
(oxiran-2-yl)methanol
(rs)-3-hydroxy-1,2-epoxypropane
oxiran-2-ylmethanol
CHEBI:30966 ,
oxiranemethanol, (s)-
oxiranemethanol, (r)-
nsc-46096
epihydrin alcohol
methanol, oxiranyl-
monoepoxide glycidol
1-propanol,3-epoxy-
glycide
1-hydroxy-2,3-epoxypropane
allyl alcohol oxide
nsc46096
3-hydroxypropylene oxide
oxiranemethanol
2,3-epoxy-1-propanol
nci-c55549
3-hydroxy-1,2-epoxypropane
2-(hydroxymethyl)oxirane
oxiranylmethanol
wln: t3otj b1q
1,2-epoxy-3-hydroxypropane
glycidyl alcohol
(rs)-oxiranemethanol
(rs)-glycidol
brn 0079782
brn 0079783
ccris 6389
ccris 6390
NCGC00090738-01
brn 0383562
einecs 209-128-3
ai3-50540
hydroxymethyl ethylene oxide
2,3-epoxypropan-1-ol
2-hydroxymethyloxiran
nsc 46096
2,3-epoxypropanol
epoxypropyl alcohol
ccris 1052
1-propanol, 2,3-epoxy-
hsdb 1819
glycidol
556-52-5
glycidol, 96%
NCGC00090738-02
2,3-epoxypropanol-1
(+/-)-glycidol
NCGC00090738-04
NCGC00090738-03
HMS3039K06
cas-556-52-5
tox21_201309
NCGC00258861-01
dtxcid60666
NCGC00253997-01
dtxsid4020666 ,
tox21_300301
ec 404-660-4
r-2,3-epoxy-1-propanol
2-oxiranemethanol
ec 209-128-3
5-17-03-00009 (beilstein handbook reference)
unii-s54cf1dv9a
s54cf1dv9a ,
FT-0601500
FT-0609741
FT-0601501
AM20100365
glycidol [iarc]
levodropropizine impurity c [ep impurity]
glycidol [mi]
glycidol [ep impurity]
d-l-glycidol
glycidol [hsdb]
dl-glycidol
glycidol-d5
CHEMBL1530150
J-502270
J-502514
oxiranyl-methanol
glycerol glycid
(+/-)-2-(hydroxymethyl)oxirane
2-oxiranylmethanol
glycerol glycide
Q-201169
STR01325
hydroxymethyloxirane
(+/-)-oxirane-2-methanol
STL483075
F0001-1460
(+/-)-glycidol, analytical standard
levodropropizine impurity c, european pharmacopoeia (ep) reference standard
glycidol; oxiran-2-ylmethanol; [(2rs)-oxiran-2-yl]methanol; levodropropizine ep impurity c; 2,3-epoxypropan-1-ol
SY013955
SY031944
mfcd00074873
CS-0016001
FT-0745851
Q418265
1246819-20-4
glycidol epoxypropyl alcohol 2,3-epoxy-1-propanol
SB40756
SB44653
PB43085
Z104476180

Research Excerpts

Overview

Glycidol (Gly) is an electrophilic low-molecular weight epoxide that is classified by IARC as probably carcinogenic to humans.

ExcerptReferenceRelevance
"Glycidol (Gly) is an electrophilic low-molecular weight epoxide that is classified by IARC as probably carcinogenic to humans. "( Quantification of the mutagenic potency and repair of glycidol-induced DNA lesions.
Aasa, J; Jenssen, D; Motwani, HV; Törnqvist, M; Vare, D, 2016
)
2.13

Bioavailability

ExcerptReferenceRelevance
" However, the real oral bioavailability may be lower."( Toxicological assessment of 3-chloropropane-1,2-diol and glycidol fatty acid esters in food.
Abraham, K; Appel, KE; Bakhiya, N; Gürtler, R; Lampen, A, 2011
)
0.61
" The oral bioavailability of G in monkeys (34."( Species differences in toxicokinetic parameters of glycidol after a single dose of glycidol or glycidol linoleate in rats and monkeys.
Harada, T; Kasamatsu, T; Kurata, Y; Nishiyama, N; Tamaki, Y; Wakabayashi, K, 2012
)
0.63
"In order to quantify the relative bioavailability of glycidol from glycidyl fatty acid esters in vivo, glycidyl palmitoyl ester and glycidol were orally applied to rats in equimolar doses."( Relative oral bioavailability of glycidol from glycidyl fatty acid esters in rats.
Abraham, K; Apel, E; Appel, KE; Bakhiya, N; Berger-Preiss, E; Creutzenberg, O; Hansen, T; Lampen, A; Schuchardt, S; Vogt, C, 2013
)
0.92

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were obtained by all 3 assays for those compounds that exhibited mutagenic activity."( Mutagenicity of alkyl glycidyl ethers in three short-term assays.
Coppinger, WJ; McCarroll, N; Oberly, TJ; Piper, CE; Robinson, D; Thompson, ED, 1981
)
0.26
" Generally, the brain tumor responses were considered equivocal, because the characteristics of potential neurocarcinogenic agents (such as statistically significant increased incidences, decreased latency and/or survival, and demonstration of dose-response relationships) were not observed."( Examination of low-incidence brain tumor responses in F344 rats following chemical exposures in National Toxicology Program carcinogenicity studies.
Boorman, GA; Hailey, JR; Haseman, JK; Melnick, RL; Neal, J; Sills, RC,
)
0.13
" The incidences of histiocytic sarcoma were increased in dosed groups of males and in females administered 50 mg/kg or greater, and the incidences in 50 and 200 mg/kg males were significantly greater than that in the vehicle control group."( Toxicology and carcinogenesis study of glycidol (CAS No. 556-52-5) in genetically modified haploinsufficient p16(Ink4a)/p19(Arf) mice (gavage study).
, 2007
)
0.61
" When tartaric acid is dosed at room temperature and immediately cooled to 100 K for imaging, individual bitartrate molecules were found."( Chemisorptive enantioselectivity of chiral epoxides on tartaric-acid modified Pd(111): three-point bonding.
Mahapatra, M; Tysoe, WT, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID743255
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.83650.000214.376460.0339AID588532; AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency15.60550.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.96620.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.09930.000229.305416,493.5996AID743075
activating transcription factor 6Homo sapiens (human)Potency54.94100.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.30600.000323.4451159.6830AID743066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (190)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (21.58)18.7374
1990's9 (4.74)18.2507
2000's36 (18.95)29.6817
2010's76 (40.00)24.3611
2020's28 (14.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.44 (24.57)
Research Supply Index5.31 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index91.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.50%)5.53%
Reviews6 (2.99%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other194 (96.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]